Journal of Clinical Oncology, Vol 18, Issue 6
(March), 2000: 1246-1253
© 2000 American Society for Clinical Oncology
Radiation Therapy and High-Dose Tamoxifen in the Treatment of Patients With Diffuse Brainstem Gliomas: Results of a Brazilian Cooperative Study
By Alberto Broniscer,
Cláudia da Costa Leite,
Vera L. Lanchote,
Telma M. S. Machado,
Lilian M. Cristófani,
and the Brainstem Glioma Cooperative Group
From the Pediatric Oncology Division, Instituto da Criança, and Department of Radiology, Hospital das Clínicas, São Paulo University Medical School; and Laboratory of Toxicology, School of Pharmaceutical Sciences, São Paulo University, Ribeirão Preto, São Paulo, Brazil.
Address reprint requests to Alberto Broniscer, MD, 221 Middle Neck Rd L-3, Great Neck, NY 11021; email vbroniscer{at}aol.com
PURPOSE: The efficacy of radiation therapy (RT) combined with tamoxifen (TX) was tested in patients diagnosed with diffuse brainstem gliomas in a multicenter trial.
PATIENTS AND METHODS: TX was administered orally (maintenance dose: 200 mg/m2 per day) along with conventional local RT and then continued for 52 additional weeks. Survival, tumoral radiologic response, and toxicity were evaluated. Compliance was assessed using pharmacokinetic measurements.
RESULTS: Of 29 patients, 27 completed RT (median dose, 54 Gy). Of 22 assessable patients, 11 (50%) had an objective radiologic response. The mean TX steady-state serum level was 2.44 µmol/L ± 1.02 µmol/L. Only three patients completed the entire course of treatment without tumoral progression or significant toxicity. Common side effects included nausea and vomiting. Hepatotoxicity (five patients), neurotoxicity (two patients), venous thrombosis (one patient), bilateral ovarian cysts (two patients), and transient neutropenia (one patient) were also observed. Median survival was 10.3 months. Only four patients remain alive without tumoral progression. The 1-year survival rate (mean ± SD) was 37.0% ± 9.5%.
CONCLUSION: This treatment combination produced no significant change in the overall poor prognosis of these patients. Most tumors responded initially to treatment but recurred as the study progressed. A minority of patients seemed to benefit from the extended use of TX. Generally, treatment was well tolerated, with good patient compliance, but we recommend continuous close monitoring for side effects. Based on our poor results, we recommend that alternative treatments be tested in patients with this type of tumor.
This article has been cited by other articles:
|
|
|
|
 
D. Frappaz, M. Schell, P. Thiesse, P. Marec-Berard, C. Mottolese, D. Perol, C. Bergeron, T. Philip, A. C. Ricci, S. Galand-Desme, et al.
Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: Final results of BSG 98 prospective trial
Neuro-oncol,
August 1, 2008;
10(4):
599 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Burzynski, T. J. Janicki, R. A. Weaver, and B. Burzynski
Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma.
Integr Cancer Ther,
March 1, 2006;
5(1):
40 - 47.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. I. Robins, M. Won, W. F. Seiferheld, C. J. Schultz, A. K. Choucair, D. G. Brachman, W. F. Demas, and M. P. Mehta
Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021
Neuro-oncol,
January 1, 2006;
8(1):
47 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Broniscer and A. Gajjar
Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist
Oncologist,
April 1, 2004;
9(2):
197 - 206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann
Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas?
Oncologist,
February 1, 2002;
7(1):
17 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
